Tanespimycin

Drug Profile

Tanespimycin

Alternative Names: 17-AAG; 17-allylamino-17-demethoxy-geldanamycin; KOS-953

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Kosan Biosciences
  • Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 05 Dec 2009 Efficacy, adverse events and pharmacodynamics data from a phase II/III trial in Multiple myeloma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
  • 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in Australia (IV)
  • 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top